EGFR and non-small cell lung carcinoma: Moreover, a number of studies mined high-dimensional clues from functional and metabolic images of 18F-FDG-PET/CT, aiming to improve clinical decision of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs) treatments for specific NSCLC patient populations (30–34).